Pulmatrix Raises $30.2 Million
Pulmatrix, a Lexington, Mass.-based developer of drug therapies for infectious and progressive respiratory diseases, has raised $30.2 million in Series B funding. Arch Venture Partners and Novartis Bioventures Fund co-led the round, and were joined by return backers Polaris Venture Partners and 5AM Ventures. The company previously raised $14.5 million. In other Pulmatrix news, the company recently received a $2.2 million grant from the National Institute of Allergy and Infectious Diseases.
2 November 2009•7 mins read
